KalVista Pharmaceuticals (NASDAQ: KALV)
KalVista Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
KalVista Pharmaceuticals Company Info
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
News & Analysis
Can KalVista Pharmaceuticals Stock Fly Higher?
Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?
Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today
Analysts say the biotech's investors could be in store for even more gains.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.